PetVivo HoldingsPETVW 35 EBITDA Margin % is -719.23% as of Dec. 2025. GuruFocus rates PETVW with a GF Score™ of 35/100. The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, PetVivo Holdings ranks worse than 93.01% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PetVivo Holdings's EBITDA for the
three
months ended in Dec. 2025 was $-2.06 Mil. PetVivo Holdings's Revenue for the
three
months ended in Dec. 2025 was $0.29 Mil. Therefore, PetVivo Holdings's EBITDA margin for the quarter that ended in Dec. 2025 was -719.23%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PetVivo Holdings EBITDA Margin % Related Terms
PetVivo Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PetVivo Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PETVW vs MODD, NMTC, CTSO: EBITDA Margin % Comparison
For the Medical Devices subindustry, PetVivo Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PetVivo Holdings EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PetVivo Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PetVivo Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PetVivo Holdings (PETVW) has a EBITDA Margin % of -719.23% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PetVivo Holdings and its competitors. According to the industry distribution chart, PetVivo Holdings ranks #759 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 93%.
Is PetVivo Holdings' EBITDA Margin % too high?
PetVivo Holdings' current EBITDA Margin % is -719.23%. Based on the distribution chart, PetVivo Holdings ranks #759 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PetVivo Holdings has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does PetVivo Holdings' EBITDA Margin % compare to MODD and NMTC?
According to the Medical Devices & Instruments industry distribution chart, PetVivo Holdings ranks #759 out of 816 companies for EBITDA Margin %. This places PetVivo Holdings in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PetVivo Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PetVivo Holdings's current EBITDA Margin % is -719.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PetVivo Holdings stock overvalued right now?
PetVivo Holdings (PETVW) has a current EBITDA Margin % of -719.23%. The current EBITDA Margin % is -719.23%. PetVivo Holdings' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PetVivo Holdings (PETVW), the current EBITDA Margin % is -719.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PetVivo Holdings Inc is an emerging biomedical device company. It is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of several patents. The company has also begun the commercialization of its product Spryng with OsteoCushion technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses.
35GF Score
Get the complete analysis for PETVW
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PETVW has been successfully added to your 
